Mylan Says Taking Action To Further Enhance Access To EpiPen Auto-Injector

(RTTNews) - Mylan N.V. (MYL) said that it is taking immediate action to further enhance access to EpiPen (epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs.

The company said it is reducing the patient cost of EpiPen Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak. For patients who were previously paying the full amount of the company's list price for EpiPen, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families as well.

Mylan has worked to help patients with commercial insurance pay as little as $0 for EpiPen Auto-Injector using the My EpiPen Savings Card.

For patients in health plans who face higher out-of-pocket costs, the company is providing immediate relief by offering a savings card for up to $300. This will effectively reduce by 50% the cost exposure for patients who would have otherwise paid the full list price for EpiPen Auto-Injector.

Mylan also is doubling eligibility for our patient assistance program to 400% of the federal poverty level. This means a family of four making up to $97,200 would pay nothing out of pocket for their EpiPen Auto-Injector.

Further, Mylan will continue to offer the EpiPen4Schools program. The program, launched in August 2012, has provided more than 700,000 free epinephrine auto-injectors and educational resources to more than 65,000 schools nationwide to help them be prepared for anaphylaxis events among students.

Mylan also is opening a pathway so that patients can order EpiPen Auto-Injector directly from the company, thereby reducing the cost.

These programs will apply to EpiPen and EpiPen Jr (epinephrine injection, USP) Auto-Injectors.